![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
S Yamada, M Isogai, Y Kagawa, N Takayanagi, E Hayashi, K Tsuji and T Kosuge
Specific [3H]nicotine binding to rat forebrain membranes was saturable and of high affinity, and it exhibited pharmacological specificity as well as stereoselectivity for nicotinic agents. There was a regional variation of specific [3H]nicotine binding in rat brain. Low concentrations of neosurugatoxin markedly inhibited specific [3H]nicotine binding in rat forebrain (IC50 = 78 nM) and the competition curve by the toxin was biphasic (pseudo-Hill slope, 0.44). Approximately 50% of [3H]nicotine binding in rat forebrain was inhibited by low concentrations (0.3-100 nM) of neosurugatoxin and the residual binding was inhibited by higher concentrations (0.3-10 microM). In the presence of 3 nM, 100 nM, and 1 microM neosurugatoxin, there was a concentration-dependent (28, 54, and 71%, respectively) loss of [3H]nicotine-binding sites (Bmax) in rat forebrain with little change in the dissociation constant (Kd). The blockade of brain [3H]nicotine-binding sites induced by neosurugatoxin was not reversed by washing. Further, the toxin (10 microM) considerably accelerated the dissociation of [3H]nicotine from its receptor sites initiated by nonlabeled (-)nicotine. These observations suggest that neosurugatoxin may allosterically regulate [3H]nicotine binding rather than competing directly. In contrast to a marked inhibition of [3H]nicotine binding, neosurugatoxin (100 nM-10 microM) had no effect on brain [3H]quinuclidinyl benzilate binding. In conclusion, the present study has shown that [3H]nicotine selectively labels nicotinic cholinergic receptors in rat brain and that neosurugatoxin is a potent noncompetitive antagonist of these receptors.
This article has been cited by other articles:
|
|
 |
|
  T. Oki, A. Toma-Okura, and S. Yamada Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration, and Salivary Secretion J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1137 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sántha, B. Sperlágh, T. Zelles, G. Zsilla, P. T. Tóth, B. Lendvai, M. Baranyi, and E. S. Vizi Multiple Cellular Mechanisms Mediate the Effect of Lobeline on the Release of Norepinephrine J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 302 - 307. [Abstract] [Full Text]
|
|
|
|
|
|
L. Teng, P. A. Crooks, P. K. Sonsalla, and L. P. Dwoskin Lobeline and Nicotine Evoke [3H]Overflow from Rat Striatal Slices Preloaded with [3H]Dopamine: Differential Inhibition of Synaptosomal and Vesicular [3H]Dopamine Uptake J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1432 - 1444. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
